Generated by Codex with GPT-5

This summary covers The Economist’s June 20th, 2026 Leaders article listed in the contents under Chinese biotech and published under the headline Wrong prescription.

The article argues that America is in danger of mistaking medical innovation for another battlefield in its technology contest with China. Chinese biotechnology has moved from imitation to genuine discovery, and American drug companies are increasingly licensing Chinese-developed molecules. Some politicians now want to treat that trend as a national-security threat, extending investment restrictions to biotech deals and even asking the Food and Drug Administration to disregard Chinese clinical-trial data.

The Economist’s case is that this would be a self-defeating response. Medicines are not semiconductors or frontier AI models. When Chinese firms discover useful drugs, the immediate beneficiaries can include American patients, American pharmaceutical companies and the global scientific base. America has legitimate reasons to worry about dependence on Chinese manufacturing for active pharmaceutical ingredients, but the article separates that supply-chain problem from the broader flow of biomedical knowledge. Shutting out Chinese science would make drug development slower, more expensive and less productive.

China’s Biotech Moment

The article presents China’s rise in biotech as striking but not mysterious. Chinese firms now run nearly a third of the world’s clinical trials, compared with a small share a decade earlier. China has become the second-largest source of new drugs after America, and in 2025 almost half of licensing deals worth at least \$50m involved Chinese firms. In some cancer-treatment categories, especially antibody-drug conjugates, Chinese companies have become unusually important sources of promising molecules.

That shift unsettles Washington because it resembles China’s ascent in other strategic industries. But the article argues that the analogy is poor. In AI and chips, American officials worry that know-how will leak from America to China and strengthen a rival. In biotech licensing, the knowledge often flows the other way: American firms buy access to Chinese discoveries and use their own strengths in late-stage trials, regulatory approval and commercial launch to bring drugs to market. If the molecule works, patients care less about where it was invented than whether it reaches them quickly and safely.

The economic case for openness is also strong. Drug discovery has become painfully inefficient. A new medicine can take more than a decade to reach the market and cost roughly \$2.8bn to develop. If American regulators ignored Chinese trial data or Congress chilled licensing deals, companies would have to repeat work, delay launches and spend more money. The likely result would be fewer drugs, higher costs and a greater chance that useful treatments reach Europe or Asia before they reach Americans.

The Wrong Kind Of Protectionism

The protectionist argument is that licensing Chinese molecules may divert capital from American biotech. The article treats this as too static. Investment is not a fixed pile that must be divided between domestic and foreign ideas. When scientific opportunities expand, capital can expand with them. The more important task is to keep America attractive as the place where promising drugs are tested, approved, financed and commercialized.

On that front, America is damaging itself. The article points to turmoil at the FDA, politicized review incentives, cuts to the National Institutes of Health and immigration policies that make the country less welcoming to the scientists it needs. These are not signs of strategic confidence. They are ways to weaken the very ecosystem that gives America its advantage in translating science into medicine.

The distinction matters because biotech leadership is not just about who discovers a molecule first. It depends on clinical expertise, regulatory credibility, capital markets, manufacturing capacity, talent and trust. America remains strong in many of those areas, but it can erode them through bad policy. If lawmakers respond to Chinese competition by rejecting Chinese data and discouraging collaboration, they may protect domestic firms from pressure while hurting patients and slowing American science.

Better Competition

The article’s conclusion is not that America should ignore all China-related risks. Dependence on China for essential drug ingredients is real, and supply chains for critical medicines deserve scrutiny. But manufacturing resilience is different from scientific isolation. The sensible response is to diversify production, strengthen domestic institutions and keep America the best place to develop and approve drugs.

The broader lesson is that rivalry should not blind policymakers to shared human gains. Cancer, infection and chronic disease do not respect national borders. If China invents an effective therapy and America helps validate, manufacture or distribute it, both countries can benefit. The world would be better off with two powerful engines of biomedical innovation than with one trying to block the other.

The article therefore frames openness as a form of strength, not naivety. America should compete hard in biotechnology by funding research, attracting talent and maintaining the world’s most trusted regulator. It should not hobble itself by pretending that useful Chinese discoveries become dangerous simply because they are Chinese. In medicine, the winning strategy is to get more good ideas into patients’ hands, wherever those ideas begin.